Spiolto Respimat

Per actuation Tiotropium 2.5 mcg, olodaterol 2.5 mcg

Maintenance bronchodilator treatment for symptomatic relief in adult patients w/ COPD.

2 puffs once daily.

Hypersensitivity to tiotropium, olodaterol, atropine or its derivatives eg, ipratropium or oxitropium.

Hypersensitivity. Discontinue use if paradoxical bronchospasm occurs. Not to be used in asthma, acute bronchospasm episodes ie, rescue therapy. Patients w/ narrow-angle glaucoma, prostatic hyperplasia or bladder neck obstruction; CV disorders eg, history of MI, unstable or life-threatening cardiac arrhythmia, hospitalization due to heart failure, paroxysmal tachycardia; ischaemic heart disease, severe cardiac decompensation, hypertrophic obstructive cardiomyopathy, HTN, aneursym; convulsive disorders or thyrotoxicosis, known or suspected QT interval prolongation & patients unusually responsive to sympathomimetic amines. Dry mouth. Hypokalemia, hyperglycemia. May cause wheezing & breathing difficulties due to benzalkonium Cl. Avoid contact w/ eyes. Not to be used in conjunction w/ other long-acting β₂-adrenergic agonists-containing medications. Concomitant use w/ halogenated hydrocarbon anaesth. May affect ability to drive & use machines. Moderate to severe renal impairment (CrCl <50 mL/min). Severe hepatic impairment. Avoid use during pregnancy. Lactation. Paed <18 yr.

Not recommended w/ anticholinergic agents. Potentiated undesirable effects w/ other adrenergic agents. Potentiated hypokalemic effect w/ xanthine derivatives, steroids or non-K sparing diuretics. Weakened or antagonized effect by β-blockers. Potentiated action on CV system w/ MAOIs, TCAs or other drugs prolonging QTc interval. Increased systemic exposure w/ ketoconazole.

Antiasthmatic & COPD Preparations

R03AL06 - olodaterol and tiotropium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.

C